Clinical trial Recruiting at 3 sites Observational Ages 5 to 8

Study on the safety and rebound effect of SAT-001 for myopia in children

Official title: A Multi-center, Open-label, Controlled Extension Study to Evaluate the Rebound Effect and Long-term Safety of Software SAT-001 for the Inhibition of Myopia Progression and Treatment in Pediatric Patients With Myopia

Run by S-Alpha Therapeutics, Inc. · NCT06742268 · Data updated 2026-11-12

This study is testing if a new software treatment for myopia can safely help children aged 5 to under 9 years old without causing problems once they stop using it.

More Myopia trials

Quick facts

Study typeObservational
Ages5 Years to 8 Years
SexAll
Enrollment40 (estimated)
SponsorS-Alpha Therapeutics, Inc.
Industry-sponsored
Locations5 sites (Seoul, Choose One... and 4 other locations)
StatusRecruiting
StartedDecember 16, 2024
Main results expectedOctober 30, 2025
Study endsJuly 30, 2026
Registry record updatedJanuary 9, 2025
Trial IDNCT06742268 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 5 to less than 9 years who completed the previous SAT-001 trial and have legal guardians willing to provide informed consent.

Probably not a fit

Patients who had less than 70% compliance in the previous trial will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the long-term safety and rebound effect of SAT-001, a Software as a Medical Device (SaMD) designed to inhibit myopia progression in children. It follows participants aged 5 to less than 9 years who completed a previous trial, assessing changes in their refractive error over a 6-month period. The study will include both treatment and control groups, with participants continuing to wear spectacles during the extension phase. The primary focus is on understanding the rebound effect that may occur after treatment cessation.

Why it matters

Potential benefit: If successful, this study could provide insights into safer and more effective treatment strategies for managing myopia in children.

How similar studies have gone: Previous studies on myopia treatments have shown varying results, but the specific focus on the rebound effect in this context is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants who have completed the previous clinical trial (SAT001-KP-002), and their legal guardians who agree to participate in this extension study and are willing to provide the signed informed consent after receiving and comprehending the explanation of the description of this clinical trial (subject under 6 can make a mark for agreement after full information and understanding)

Exclusion Criteria:

* Participants in the study group of the previous clinical trial (SAT001-KP-002) with a compliance rate of less than 70% (overall compliance throughout the study period).
* Other reasons for participation in the trial at the discretion of the investigator

Where it's running

  • Kangbuk Samsung Hospital
    Seoul, Choose One..., South Korea
    Recruiting
  • Hallym University Dongtan Sacred heart Hospital
    Hwaseong-si, Gyeonggi-do, South Korea
    Recruiting
  • Gachon University Gil Medical Center
    Incheon, South Korea
    Recruiting
  • Seoul Asan Medical Center
    Seoul, Choose One..., South Korea
    Not yet recruiting
  • Chung-Ang University Gwang Myeong Hospital
    Gwangmyeong, South Korea
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.